NovaBridge Biosciences
NBP Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.22
KIRA · Stoqly’s AI analyst, in plain words
- NovaBridge Biosciences lost $46.3M in fiscal 2025.
- Free cash flow was −$20.6M in fiscal 2025, — of revenue.
Market cap
$11.6M
P/E
—
Revenue
—
Net income
−$46.3M
Free cash flow
−$20.6M
Operating margin
—
NovaBridge Biosciences in 30 seconds · fiscal 2025
Does it make a profit?
−$46.3M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What NovaBridge Biosciences does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 7, 2026
- Legal name
- NovaBridge Biosciences
- CIK
- 0001778016
NovaBridge Biosciences · NBP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $13.8M | −$1.6M | $0.6M | — | — |
| Revenue growth | −94.2% | −111.2% | — | — | — |
| Gross margin | 47.3% | 354.6% | — | — | — |
| Operating margin | — | 3,422.2% | −11,395.1% | — | — |
| Net income | −$366M | −$371M | −$208M | −$22.2M | −$46.3M |
| Net margin | −2,648.7% | 23,923.5% | −32,868.5% | — | — |
| Diluted EPS | −$48.07 | −$45.08 | −$25.07 | −$2.76 | −$4.83 |
| Cash | |||||
| Cash from operations | −$153M | −$160M | −$184M | −$52.7M | −$20.6M |
| Capital expenditure | $4.7M | $2.1M | $0.2M | $0.0M | $0.0M |
| Free cash flow | −$157M | −$162M | −$184M | −$52.7M | −$20.6M |
| FCF margin | −1,139.5% | 10,443.8% | −29,107.9% | — | — |
| Share count change | 11.1% | 8.6% | 0.9% | −2.5% | 18.0% |
| Debt and strength | |||||
| Cash and short-term investments | $671M | $377M | $312M | $173M | $211M |
| Debt incl. finance leases | — | $2.7M | $4.2M | — | — |
| Shareholders' equity | $715M | $418M | $243M | $201M | $231M |
| Current ratio | 7.7x | 4.8x | 5.7x | 20.9x | 8.1x |
| Interest coverage | — | −53,078.0x | −706.0x | — | — |
| Returns and quality | |||||
| Return on capital | — | −96.4% | — | — | — |
| Return on equity | −46.4% | −65.5% | −62.9% | −10.0% | −21.4% |
| Return on tangible equity | −54.5% | −96.4% | −91.4% | −11.1% | −20.0% |
| Piotroski F-score | 1 | 1 | 4 | — | — |
| Altman Z'' | — | 1.1 | −5.6 | 2.2 | −6.1 |
Insiders bought, 12 months
$0.6M
1 insider
Insiders sold, 12 months
$0.2M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
NovaBridge Biosciences · NBP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.22 a share, the company is worth $11.6M.
Source: SEC EDGAR XBRL filings (CIK 0001778016). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.